Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient-reported outcomes in melanoma patients treated with immune checkpoint inhibitors
NL-OMON51119Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Apr 2021
- Countries
- 1
01
Overview
Open-label, single-arm trial in melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Health-related quality of life. Started Apr 2021; status: recruiting.
02
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON51119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51119.